Author

Gary Altwerger

Yale University - Cited by 1,216
Title
Cited by
Year
Integrated mutational landscape analysis of uterine leiomyosarcomas
J Choi, A Manzano, W Dong, S Bellone, E Bonazzoli, L Zammataro, X Yao, ...Proceedings of the National Academy of Sciences 118 (15), e2025182118, 2021202
46
2021
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
S Lopez, E Perrone, S Bellone, E Bonazzoli, B Zeybek, C Han, ...Oncotarget 11 (5), 560, 2020202
29
2020
Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan …
E Perrone, S Lopez, B Zeybek, S Bellone, E Bonazzoli, S Pelligra, ...Frontiers in Oncology 10, 118, 2020202
28
2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
B Zeybek, A Manzano, A Bianchi, E Bonazzoli, S Bellone, N Buza, P Hui, ...Scientific Reports 10 (1), 973, 2020202
28
2020
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
S Bellone, DM Roque, ER Siegel, N Buza, P Hui, E Bonazzoli, ...Cancer 128 (6), 1206-1218, 2022202
25
2022
Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial …
E Perrone, P Manara, S Lopez, S Bellone, E Bonazzoli, A Manzano, ...Molecular Oncology 14 (3), 645-656, 2020202
23
2020
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
C Han, E Perrone, B Zeybek, S Bellone, J Tymon-Rosario, G Altwerger, ...Gynecologic Oncology 156 (2), 430-438,
20
2020
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics …
S Bellone, DM Roque, ER Siegel, N Buza, P Hui, E Bonazzoli, ...Annals of Oncology 32 (8), 1045-1046, 2021202
19
2021
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
J Tymon-Rosario, ER Siegel, S Bellone, J Harold, N Adjei, B Zeybek, ...Gynecologic oncology 163 (1), 93-99, 2021202
12
2021
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
EM Webster, GS Yadav, S Gysler, B McNamara, J Black, J Tymon-Rosario, ...Gynecologic Oncology Reports 34, 0667, 2020202
10
2020
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate …
JR Tymon-Rosario, P Manara, DD Manavella, S Bellone, TMP Hartwich, ...Gynecologic Oncology 166 (1), 117-125, 2022202
9
2022
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
D Roque, E Siegel, N Buza, S Bellone, DA Silasi, G Huang, V Andikyan, ...Gynecologic Oncology 162, S5, 2021202
8
2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
B Zeybek, E Webster, N Pogosian, J Tymon-Rosario, A Balch, G Altwerger, ...Journal of Gynecologic Oncology 32 (6), 2021202
7
2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
J Tymon-Rosario, E Bonazzoli, S Bellone, A Manzano, S Pelligra, ...Gynecologic Oncology 163 (2), 334-341, 2021202
7
2021
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Elimusertib (BAY189344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJ Harold, S Bellone, DD Manavella, L Mutlu, B McNamara, TMP Hartwich, ...Gynecologic Oncology 168, 17-16, 2023202
5
2023
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma
E Bonazzoli, S Bellone, L Zammataro, B Gnutti, A Guglielmi, S Pelligra, ...Gynecologic oncology 158 (), 769-775, 2020202
3
2020
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
S Damast, CJ Tien, M Young, G Altwerger, E RatnerJournal of Contemporary Brachytherapy 14 (1), 66-71, 2022202
3
2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
G Yadav, DM Roque, S Bellone, DD Manavella, TMP Hartwich, M Zipponi, ...Gynecologic Oncology 166 (2), 51-57, 2022202
3
2022
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian …
Trastuzumab deruxtecan (DS-801a), a HER-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian …D Mauricio, S Bellone, L Mutlu, B McNamara, DD Manavella, ...Gynecologic Oncology 170, 38-45, 030
2
2023
Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
DM Roque, ER Siegel, N Buza, S Bellone, DA Silasi, GS Huang, ...British Journal of Cancer 16 (1), 1695-1703, 0
2
2022

Referred From: https://scholar.google.com/citations?user=VSY024MAAAAJ&hl=en

Cited by
Citations 1216
h-index 22
i10-index 33
Open Access Journals